Advertisement
- China
- /
- Metals and Mining
- /
- SZSE:002428
Yunnan Lincang Xinyuan Germanium IndustryLTD Full Year 2024 Earnings: Beats Expectations
Yunnan Lincang Xinyuan Germanium IndustryLTD (SZSE:002428) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥767.4m (up 14% from FY 2023).
- Net income: CN¥53.1m (up by CN¥46.1m from FY 2023).
- Profit margin: 6.9% (up from 1.0% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.08 (up from CN¥0.01 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Yunnan Lincang Xinyuan Germanium IndustryLTD Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 100%.
Looking ahead, revenue is forecast to grow 5.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Metals and Mining industry in China.
Performance of the Chinese Metals and Mining industry.
The company's shares are down 6.1% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Yunnan Lincang Xinyuan Germanium IndustryLTD's balance sheet and an in-depth analysis of the company's financial position.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:002428
Yunnan Lincang Xinyuan Germanium IndustryLTD
Engages in the research and development, deep processing, germanium mining, pyrometallurgical enrichment, hydrometallurgical purification, and zone melting refining in China.
Moderate growth potential with mediocre balance sheet.
Market Insights
Advertisement
Weekly Picks
ST
stuart_roberts on Unicycive Therapeutics ·
Looking to be second time lucky with a game-changing new product
Fair Value:US$21.5360.5% undervalued
135 followersusers have followed this narrative
0 commentsusers have commented on this narrative
19 likesusers have liked this narrative
DE
Degen_GCR on Everpure ·
Second order memory play likely to double in a year
Fair Value:US$18053.1% undervalued
19 followersusers have followed this narrative
1 commentusers have commented on this narrative
12 likesusers have liked this narrative
DO
Double_Bubbler on Intuitive Machines ·
Intuitive Machines: To The Moon and Beyond!
Fair Value:US$42.315.7% undervalued
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
5 likesusers have liked this narrative
YI
yiannisz on AppLovin ·
AppLovin’s AI Engine Is Printing Profit
Fair Value:US$989.2454.2% undervalued
30 followersusers have followed this narrative
2 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Recently Updated Narratives
MA
MarkoVT on COVER ·
Significant headwinds will temper expectations for FY2027
Fair Value:JP¥2.28k36.9% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
KA
kapirey on Unicycive Therapeutics ·
Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization
Fair Value:US$9.177.2% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
KA
kapirey on Guming Holdings ·
A scaled, high-growth, franchise-driven beverage leader with strong penetration in China
Fair Value:HK$47.5650.6% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
GO
GoldenSands on QuantumScape ·
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality
Fair Value:US$8589.8% undervalued
108 followersusers have followed this narrative
2 commentsusers have commented on this narrative
31 likesusers have liked this narrative
KI
Kingman1152 on NVIDIA ·
NVIDIA will see a profit margin surge of 55% in the next 5 years
Fair Value:US$305.226.0% undervalued
70 followersusers have followed this narrative
2 commentsusers have commented on this narrative
24 likesusers have liked this narrative
TR
tripledub on Meta Platforms ·
The $135 Billion Bet That Should Make Every Shareholder Nervous
Fair Value:US$74016.7% undervalued
36 followersusers have followed this narrative
3 commentsusers have commented on this narrative
33 likesusers have liked this narrative
